0.0001
0.0000
(0.00%)
Delayed:
9:32AM EDT
OTCMKTS
data delayed by 15 mins -
Disclaimer
Currency in USD
| Range | - |
| 52 week | - |
| Open | - |
| Vol / Avg. | 0.00/68,912.00 |
| Mkt cap | 54,181.00 |
| P/E | - |
| Div/yield | - |
| EPS | 0.00 |
| Shares | 541.81M |
| Beta | - |
| Inst. own | 0% |
Key stats and ratios
| Q3 (Sep '09) | 2008 | |
| Net profit margin | - | -1628.04% |
| Operating margin | - | -1628.04% |
| EBITD margin | - | -988.96% |
| Return on average assets | -3640.38% | -4748.23% |
| Return on average equity | - | - |
| Carbon Disclosure Rating | - | - |
Address
External links
Discussion Group - Google Finance
Advertisement
Description
Thomas Pharmaceuticals, Ltd. (Thomas Pharmaceuticals) develops and markets over the counter non-prescription healthcare products. Acid+All is the Company�s first product. Acid+All is a calcium-enriched, sugar free, anti-gas antacid tablet. The Company was a wholly owned subsidiary of iVoice, Inc. (iVoice). As of December 31, 2008, the Company did not produce any products.
Officers and directors
| Mark Meller | President, Chief Executive Officer, Director | |
| Frank V. Esser | Director |